CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $24 | $21 | $18 | $12 |
| % Growth | 14.4% | 15.6% | 48% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $23 | $20 | $17 | $11 |
| % Margin | 94.9% | 94.5% | 93.7% | 92.6% |
| R&D Expenses | $10 | $12 | $8 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $22 | $24 | $21 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | -$0 | $0 |
| Operating Expenses | $32 | $34 | $29 | $30 |
| Operating Income | -$9 | -$14 | -$12 | -$19 |
| % Margin | -38.3% | -64.5% | -67% | -153.2% |
| Other Income/Exp. Net | -$4 | -$4 | -$3 | -$4 |
| Pre-Tax Income | -$13 | -$17 | -$16 | -$23 |
| Tax Expense | $8 | -$1 | -$0 | $0 |
| Net Income | -$22 | -$17 | -$16 | -$23 |
| % Margin | -90.4% | -80.3% | -85.7% | -183.8% |
| EPS | -0.17 | -0.13 | -0.13 | -0.21 |
| % Growth | -30.8% | 0% | 38.1% | – |
| EPS Diluted | -0.17 | -0.13 | -0.13 | -0.21 |
| Weighted Avg Shares Out | 132 | 128 | 122 | 109 |
| Weighted Avg Shares Out Dil | 132 | 128 | 122 | 109 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $5 | $4 | $4 | $4 |
| Depreciation & Amortization | $1 | -$0 | $1 | $1 |
| EBITDA | -$8 | -$14 | -$11 | -$18 |
| % Margin | -32.5% | -65% | -61.7% | -146.8% |